GSK plc will present the latest research from across its respiratory portfolio at the upcoming ERS Congress 2025, from 27th September to 1st October in Amsterdam, the Netherlands. GSK presentations at ERS meaningfully advance the science surrounding respiratory diseases including asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic obstructive pulmonary disease (COPD), as well as refractory chronic cough (RCC) and infectious respiratory diseases. The new research supports the company’s strategy of addressing the underlying drivers of disease to help reduce exacerbations, slow the decline of lung function by limiting disease progression, and decrease the burden on healthcare resources including hospitalisation.
Key presentations will be shared from GSK’s portfolio of biologics to address type 2 inflammation, including depemokimab, an investigational, ultra-long-acting monoclonal antibody, and mepolizumab, a monoclonal antibody indicated to treat several diseases with underlying type 2 inflammation:
• Sub-analyses from the SWIFT-1 and SWIFT-2 trials in asthma with type 2 inflammation, characterised by blood eosinophil count, will further explore different groups of patients with asthma who could benefit from depemokimab. Asthma patient sub-groups include those with comorbid CRSwNP, an important population as up to 40% of severe asthma patients also have CRSwNP (OA2334), and patients requiring medium- or high-dose inhaled corticosteroids (ICS) at baseline (PA2469).
• Additional data from SWIFT-1 and SWIFT-2 will explore the potential for depemokimab to achieve clinical remission in asthma patients with type 2 inflammation, with the aim to advance treatment goals beyond symptom control (PA2478).
• Presentation of data from the ANCHOR-1 and ANCHOR-2 trials in CRSwNP will explore the potential impact of depemokimab on early and sustained improvements in patient reported outcomes (OA2335).
• Additional analyses from mepolizumab phase III development programme in COPD including an indirect treatment comparison from MATINEE which will contextualise the results compared to another approved COPD biologic. The analysis focuses on the risk of exacerbation and the change in Saint George's Respiratory Questionnaire (SGRQ) in patient groups examined in other COPD biologic trials (PA488). Additionally, pooled phase III results from MATINEE, METREX and METREO will examine the use of mepolizumab in a wide spectrum of patients with COPD, including those with varying airflow obstruction levels and irrespective of severe exacerbation history (PA4585).
Additional key presentations will be shared from GSK’s portfolio of inhaled therapeutics, including fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and salbutamol metered-dose inhaler (MDI) with a low global warming potential propellant. Several of these presentations reflect ongoing research into the earlier use of maintenance therapies, efforts to support symptom control and reduce the risk of exacerbations, while others explore sustainable approaches to asthma and COPD management.
Expanding our commitment to the prevention of infectious respiratory diseases, GSK will present new data on respiratory syncytial virus (RSV) vaccination in younger adults at risk of illness and infection due to certain underlying conditions. In addition, a post-hoc analysis of the pivotal AReSVi-006 trial will be presented, evaluating efficacy in adults with asthma and COPD, including impact on exacerbations and the use of corticosteroids and antibiotics.
Mepolizumab is a monoclonal antibody that targets and binds to IL-5, a key messenger protein (cytokine) in type 2 inflammation. Mepolizumab has been developed for the treatment of a range of diseases with underlying type 2 inflammation. It is currently approved for use in the US and Europe across four IL-5 mediated conditions. Mepolizumab is approved for the treatment of COPD in the US. Regulatory submissions in COPD are under review in several countries, including China and the EU.
Depemokimab, a monoclonal antibody that targets IL-5, is the first ultra-long-acting biologic to be evaluated in phase III trials of patients with asthma with type 2 inflammation characterised by blood eosinophil count (SWIFT trials) or chronic rhinosinusitis with nasal polyps (CRSwNP) (the ANCHOR trials). Depemokimab's extended half-life, high-binding affinity and potency, supported six-monthly (26 week) dosing regimens in these trials, and demonstrated early and sustained of type 2 inflammation and IL-5 activity. The phase III programme includes evaluation of depemokimab in other diseases with underlying type 2 inflammation including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) and COPD. Depemokimab is an investigational product and is not approved for use in any country. Regulatory submissions are under review, including in the US, China, Japan and the EU.
GSK continues to build on decades of pioneering work to deliver more ambitious treatment goals, develop the next generation standard of care, and redefine the future of respiratory medicine for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, GSK is focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim of modifying the underlying disease dysfunction and preventing progression.
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
|